References
1. Hill, L., Alousi, A., Kebriaei, P., Mehta, R., Rezvani, K., Shpall,
E. New and emerging therapies for acute and chronic graft versus host
disease. Therapeutic Advances in Hematology. 2018; 9:21-46.
2. Al-Homsi, A. S., et al. Bortezomib for the prevention and treatment
of graft-versus-host-disease after allogenic hematopoietic stem cell
transplantation. Experimental Hematology. 2016; 44: 771-777.
3. Kuroda, J., et al. Bortezomib
for post-allogenic hematopoietic stem transplantation relapse and GVHD
in multiple myeloma: a single institute experience. International
Journal of Hematology. 2010; 92: 669-672.
4. Kumar, S., Mohammadpour, H., Cao, X. Targeting Cytokines in GVHD
Therapy. Journal of Immunology research and therapy. 2017. 2: 90-99.
5. Toubai, T., Sun, Y., Reddy, P. GVHD Pathophysiology: is acute
different from chronic? Best practice and research: Clinical
haematology. 2008. 21: 101-117.
6. Ram, R. and Storb, R. Pharmacologic Prophylaxis Regimens for Acute
GVHD – Past, Present, and Future. 2013. 54: 1591-1601.
7. Vodanovic-Jankovic, S., Hari P., Jacobs, P., Komorowski, R.,
Drobyski, W. R. NF-κB as a target for the prevention of
graft-versus-host disease: comparative efficacy of bortezomib and
PS-1145 2006.
8. Sun, Kai, E.C, Danice, Anyer, Miriam R, et al. Differential Effects
of proteasome inhibition by bortezomib on murine acute graft-versus-host
disease (GVHD): delayed administration of bortezomib results in
increased GVHD-dependent gastrointestinal toxicity. Blood. 2005
106:3293-3299; doi: https://doi.org/10.1182/blood-2004-11-4526
9. Malard F, Labopin M, Yakoub-Agha I, et al. Rituximab-based first-line
treatment of cGVHD after allogeneic SCT: results of a phase 2
study. Blood 2017; 130 (20): 2186–2195.
doi: https://doi.org/10.1182/blood-2017-05-786137
10. Carpenter PA, MacMillan ML. Management of acute graft-versus-host
disease in children. The Pediatric clinics of North America .
2010;57(1):273-295. doi: 10.1016/j.pcl.2009.11.007
11. Drobyski, W.R., Pasquini, M., Kovatovic, K. et al. Tocilizumab for
the treatment of steroid refractory graft-versus-host disease.Biol Blood Marrow Transplant . 2011; 17: 1862–1868
12. Koreth, J., Stevenson, K.E., Kim, H.T. et al. Bortezomib-based
graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor
transplantation. J Clin Oncol . 2012; 30: 3202–320
13. Koreth, J., Stevenson, K.E., Kim, H.T. et al. Bortezomib,
tacrolimus, and methotrexate for prophylaxis of graft-versus-host
disease after reduced-intensity conditioning allogeneic stem cell
transplantation from HLA-mismatched unrelated donors. Blood .
2009; 114: 3956–3959
14. Pai, C. S., Hsiao, H., Sun, K. et al. Therapeutic benefit of
bortezomib on acute GVHD is tissue specific and is associated with IL-6
levels. Biol Blood Marrow Transplant. 2014; 20: 1899-19020.
15. BS Sleight, KW Chan, TM Braun, A Serrano and AL Gilman. Infliximab
for GVHD therapy in children Bone Marrow Transplantation (2007) 40,
473–480.